A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study. (February 2020)

• Record Type: Journal Article
• Authors: Gordon, Max J.; Sitlinger, Andrea; Salous, Tareq; Alqahtani, Hamood; Churnetski, Michael; Rivera, Xavier; Wisniewski, Paul; Cohen, Jonathon; Patel, Krish; Shadman, Mayzar; Choi, Michael; Hill, Brian; Stephens, Deborah; Persky, Daniel; Brander, Danielle; Danilov, Alexey V.
• Is Part Of: Leukemia research. Volume 89(2020)
• Publication Date: 2020-02
• Subjects: Chronic lymphocytic leukemia -- Ibrutinib -- Prognostic index; Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/j.leukres.2020.106302
• Languages: English
• ISSNs: 0145-2126

Abstract

Highlights: The CLL international prognostic index (CLL-IPI) may not be applicable to CLL patients treated with targeted therapies. Especially with ibrutinib which demonstrates improved efficacy in patients with adverse features. We report a clinical tool which stratifies CLL treated with ibrutinib into low, intermediate and high risk groups.